Zacks: Merck will benefit from Schering deal

Merck needs the Schering-Plough deal, a new Zacks analyst report states. Schering's still-on-patent drugs will help make up Merck's shortfalls as its branded meds start to face generic competition. Plus, Zacks sees "immediate synergies"--read cost-cutting opportunities--for the two companies' cholesterol drugs partnership. Report [1]